MannKind Corporation [MNKD] Is Still Undervalued at $2.91

In a recent bid MannKind Corporation [MNKD] faced a contemporary bid of $2.91 yielding a -2.29% decline where 1.38 million shares have exchanged hands over the last week. MNKD amount got a fall by -2.51% or -$0.08 versus $2.99 at the end of the prior session. This change led market cap to move at 666.14M, putting the price 264.37% below the 52-week high and -8.91% above the 52-week low. The company’s stock has a normal trading capacity of 1.38 million shares while the relative volume is 0.95.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .


On 1, December 2020, MannKind and MidCap Amend Credit Facility. According to news published on Yahoo Finance, $10 million funded immediately.

Analyst Birdseye View:

The most recent analyst activity for MannKind Corporation [NASDAQ:MNKD] stock was on October 25, 2019, when it was Initiated with an Overweight rating from Cantor Fitzgerald, which also raised its 12-month price target on the stock to $3. Before that, on December 24, 2019, Oppenheimer Recapitulated an Outperform rating and elevated its amount target to $2.50. On May 14, 2019, BTIG Research Initiated a Buy rating and boosted its price target on this stock to $3. On March 04, 2019, SVB Leerink Initiated an Outperform rating and increased its price target to $3. On February 22, 2019, SVB Leerink Initiated an Outperform rating and increased its price target to $3. On February 28, 2018, Maxim Group Downgrade a Sell rating and boosted its amount on this stock to $1. On November 01, 2017, Maxim Group Downgrade a Hold rating. On October 10, 2017, H.C. Wainwright Initiated a Buy rating and amplified its amount target to $7.

In the past 52 weeks of trading, this stock has oscillated between a low of $0.80 and a peak of $3.20. Right now, the middling Wall Street analyst 12-month amount mark is $3.00. At the most recent market close, shares of MannKind Corporation [NASDAQ:MNKD] were valued at $2.91. According to the average price forecast, investors can expect a potential return of -3.33%.


MannKind Corporation [NASDAQ:MNKD] most recently reported quarterly sales of 15.35 billion, which represented growth of 5.50%. This publicly-traded organization’s revenue is $270,549 per employee, while its income is -$222,760 per employee. This company’s Gross Margin is currently 60.30%, its Operating Margin is -56.60%, its Pretax Margin is -82.34, and its Net Margin is -82.34.

It shows enduring liability to assets at 1.32 while looking for an extended time period.

Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 2.94 points at 1st support level, the second support level is making up to 2.90. But as of 1st resistance point, this stock is sitting at 3.06 and at 3.12 for 2nd resistance point.

MannKind Corporation [MNKD] reported its earnings at -$0.05 per share in the fiscal quarter closing of 9/29/2020. The Analysts for Wall Street were expecting to report its earnings at -$0.05/share signifying the difference of 0 and 0.00% surprise value. Comparing the previous quarter ending of 6/29/2020, the stated earnings were -$0.05 calling estimates for -$0.05/share with the difference of 0 depicting the surprise of 0.00%.

Important Ratio’s To Watch

Meanwhile, turning our focus to liquidity, the Current Ratio for MannKind Corporation [NASDAQ:MNKD] is 0.60. Likewise, the Quick ratio is also the same, showing Cash ratio at 0.77. Now if looking for a valuation of this stock’s amount to sales ratio it’s 4.00.

Insider Stories

The most recent insider trade was by Binder Steven B., Chief Financial Officer, and it was the purchase of 1522.0 shares on Jul 31. Tross Stuart A, the Chief People & Workpl Officer, completed a purchase of 5000.0 shares on Jul 31. On Jul 31, Kendall David M, Chief Medical Officer, completed a purchase of 4041.0 shares.